Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 8 Univariate and multivariate model of variables associated with ADR

From: Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study

Variable

Crude OR (95% CI)

P value

Adjusted OR (95% CI)a

P value

Demographics

 Age (mean ± SD in years)

1.03 (1.02, 1.04)

< 0.001

 Sex

      Male

1

1

      Female

1.28 (0.94, 1.75)

0.117

1.53 (1.06, 2.20)

0.024

Clinical background

 History of drug allergy

      Yes

0.76 (0.29, 2.00)

0.577

      No

1

1

 Presence of comorbidity

      Yes

2.26 (1.68, 3.06)

< 0.001

      No

1

1

 COVID-19 category

      Patient under investigation

1

1

      Stage 1

0.25 (0.03, 2.08)

0.202

      Stage 2

0.67 (0.30, 1.48)

0.319

      Stage 3

2.45 (1.18, 5.07)

0.016

2.58 (1.20, 5.55)

0.015

      Stage 4

12.11 (5.62, 26.10)

< 0.001

4.17 (1.79, 9.73)

0.001

      Stage 5

6.47 (2.52, 16.60)

< 0.001

 Number of COVID-19 drug(s)

3.94 (3.20, 4.85)

< 0.001

3.34 (2.51, 4.44)

< 0.001

  1. aForward and backward LR applied. Hosmer and Lemeshow = 0.121. Classification table = 83.2. No multicollinearity was detected. ROC = 0.83 (0.79, 0.86; P value ≤ 0.001). Only variables with P value < 0.05 were mentioned in the AOR